top of page
ALS | Parkinson's Disease | Cancer
Stroke | Alzheimer's Disease
A robust pipeline
of disease modifying
medicines
ASHA-091
Alzheimer's, Parkinson's
ALS, Stroke, Post-viral Illness
ASHA-624
ALS, MS, Glaucoma
Peripheral Neuropathies
Novel Design Lead Optimization IND-Enabling Clinical Trials
Target - Mitochondrial DRP1
Target - SARM1
Undisclosed
PRISM™ Novel Design Program
Target - Multiple
Target Overview - Lead Development Candidate Programs
ASHA-091 is a highly selective inhibitor of the key mitochondria regulatory protein DRP1. ASHA-091 restores mitochondria to a healthy functional state.
​
Mitochondrial dysfunction is a key driver of neurodegeneration and certain types of infectious and post-infection illness. ASHA-091 has broad therapeutic indications with demonstrate disease modifying efficacy and robust safety.
bottom of page